Literature DB >> 21953349

Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS').

Jose Luis Rodriguez-Garcia1, Maria Laura Bertolaccini, Maria Jose Cuadrado, Giovanni Sanna, Oier Ateka-Barrutia, Munther A Khamashta.   

Abstract

OBJECTIVES: Although the medical literature currently provides a growing number of isolated case reports of patients with clinically well-defined antiphospholipid syndrome (APS) and persistently negative antiphospholipid antibodies (aPL), there are no studies including a series of patients addressing the clinical features of this condition.
METHODS: The authors assessed clinical manifestations of APS in 154 patients: 87 patients with seropositive APS and 67 patients with thrombosis and/or pregnancy morbidity persistently negative for aPL and presenting with at least two additional non-criteria manifestations of APS (the so-called 'seronegative APS', SN-APS). Patients were interviewed at the time of recruitment, and a retrospective file review was carried out.
RESULTS: There were no significant differences in the frequency of thrombotic events or obstetric morbidity in patients with SN-APS versus patients with seropositive APS: deep vein thrombosis (31.4% vs 31.0%), pulmonary embolism (23.8% vs 28.7%), stroke (14.9% vs 17.2%), transient ischaemic attack (11.9% vs 10.3%), early spontaneous abortions (67.1% vs 52.1%), stillbirths (62.5% vs 59.4%), prematurity (28.1% vs 21.7%) or pre-eclampsia (28.1% vs 23.1%).
CONCLUSIONS: Classic and SN-APS patients show similar clinical profiles. The results suggest that clinical management in patients with APS should not be based only on the presence of conventional aPL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953349     DOI: 10.1136/annrheumdis-2011-200614

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

Review 1.  Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease.

Authors:  M Ángeles Martínez-Zamora; Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Annexin-A5 resistance and non-criteria antibodies for the diagnosis of seronegative antiphospholipid syndrome.

Authors:  Virginie Planche; Arsene Mékinian; Théo Ghelfenstein Ferreira; François Delhommeau; Catherine Johanet; Grigorios Gerotziafas; Marie Bornes; Jonathan Cohen; Gilles Kayem; Olivier Fain
Journal:  Clin Rheumatol       Date:  2020-01-10       Impact factor: 2.980

Review 3.  Diagnosis and management of the antiphospholipid syndrome.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Blood Rev       Date:  2017-07-30       Impact factor: 8.250

Review 4.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

5.  The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.

Authors:  Songwang Hou; Paul E Harper; Nathalie Bardin; Ming Zhao
Journal:  J Immunol Methods       Date:  2016-10-23       Impact factor: 2.303

6.  Diagnostic value of antibodies to phosphatidylserine/prothrombin complex for antiphospholipid syndrome in Chinese patients.

Authors:  Lei Zhu; Chun Li; Na Liu; Xin Yang; R L Jia; Rong Mu; Yin Su; Z G Li
Journal:  Clin Rheumatol       Date:  2017-01-03       Impact factor: 2.980

7.  Influence of Phosphatidylethanolamine Concentration and Composition on the Detection of Antiphosphatidylethanolamine Antibodies by ELISA.

Authors:  Ke Ke; Zachariah I Strango; Paul E Harper; Ming Zhao
Journal:  J Clin Lab Anal       Date:  2016-04-07       Impact factor: 2.352

Review 8.  Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Authors:  Savino Sciascia; Mary-Carmen Amigo; Dario Roccatello; Munther Khamashta
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

9.  Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?

Authors:  Francesca Pregnolato; Cecilia B Chighizola; Susan Encabo; Zakera Shums; Gary L Norman; Armando Tripodi; Veena Chantarangkul; Tiziana Bertero; Valeria De Micheli; Maria Orietta Borghi; Pier Luigi Meroni
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

10.  Antiphospholipid syndrome in Sarawak: real world experience in a developing country.

Authors:  C L Teh; T S Leong
Journal:  Clin Rheumatol       Date:  2014-05-16       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.